Adaptive Biotechnologies shares rise 5.97% premarket after reporting strong Q2 financial results.

Adaptive Biotechnologies Corporation rose 5.97% in premarket trading, driven by positive financial results for the second quarter of 2025. The company reported 42% MRD revenue growth, 37% clonoSEQ volume growth, and positive MRD adjusted EBITDA, leading to an increase in MRD revenue guidance. Additionally, the company's earnings exceeded Wall Street expectations, with a loss of $25.6 million, or 17 cents per share, compared to the expected loss of 24 cents per share.